# AMETEK Inc. (AME) **Exchange:** NYSE **Coverage as of:** 2026-Q2 **Updated:** 2026-05-28 **Report type:** Primer (steps 1–3 of 19) **API endpoint:** GET /api/v1/research/AME/primer ## Business Model --- source: coverage-next-full type: step step: 01 title: Business Model ticker: AME generated: 2026-05-28 --- ### Step 01 — Business Model: AMETEK Inc. #### 1. Executive Summary AMETEK is a **decentralized acquisition compounder**: ~135 differentiated business units, each operating semi-autonomously in narrow industrial niches with 20-40% market share, glued together by a corporate operating system (the "AMETEK Growth Model") and a centralized M&A engine. The model has compounded EPS at ~10% CAGR for two decades by combining ~3% organic growth, ~3-5pts of M&A contribution, and operating leverage from continuous margin expansion [S1][S2]. Two reportable segments — EIG (instruments, 70% of revenue) and EMG (electromechanical, 30%) — share the same operating-excellence playbook but serve different cyclicality patterns [S2]. #### 2. Key Data Points **Two-Segment Structure (FY2025)** [S2] - **Electronic Instruments Group (EIG)** — ~$5.0B revenue, ~28-29% operating margin - Process & Analytical Instrumentation: ~70% of EIG (~$3.5B) - Aerospace & Power Instrumentation: ~30% of EIG (~$1.5B) - **Electromechanical Group (EMG)** — ~$2.4B revenue, ~23-24% operating margin (record) - Automation & Engineered Solutions: ~70% of EMG (~$1.7B) - Aerospace: ~30% of EMG (~$0.7B) **AMETEK Growth Model (4 pillars)** [S3] 1. **Operational Excellence** — lean, sourcing, pricing → 200-400bps margin uplift on acquisitions 2. **Strategic Acquisitions** — bolt-on at 6-8x EBITDA pre-synergies → ROIC ramps to 15%+ in 3 yrs 3. **Global & Market Expansion** — China/India/SE Asia geographic + adjacency moves 4. **New Product Development** — ~12-15% of revenue from products launched in last 3 years **Customer / Market Mix** [S2][S4] - ~135 business units; no single business >5% of total revenue - Top 5 customers <10% of revenue (highly diversified) - ~25% recurring/aftermarket revenue (service + replacement parts) - Geographic: US ~55%, Europe ~22%, Asia ~17%, RoW ~6% #### 3. Value Chain & Layer Map ``` ┌─────────────────────────────────────────────────────┐ │ AMETEK CORPORATE (Berwyn, PA) │ │ - Capital allocation (M&A engine) │ │ - Operating system (AGM) │ │ - Functional centers (tax, treasury, legal, HR) │ └────────────────┬────────────────┬───────────────────┘ │ │ ┌──────────────▼──┐ ┌───────▼──────────────┐ │ EIG │ │ EMG │ │ ~$5.0B / 70% │ │ ~$2.4B / 30% │ │ ~28-29% margin │ │ ~23-24% margin │ └──────┬──────────┘ └───────┬──────────────┘ │ │ ┌──────────────┼────────────┐ ┌──────┼──────────┐ ▼ ▼ ▼ ▼ ▼ Process & Aerospace & Materials Automation & Aerospace Analytical Power Analysis Engineered Specialty Instr. Instr. (FARO, Solutions Metals (Spectro, (Aerospace Cameca, (precision (Stripping Land, actuators, ultra- motion, foils, pressure, thermal mgmt, precision connectors) engines) gas analyz.) sensors) tech) ``` **Layer mapping:** - **Layer 1 — Corporate:** Capital allocation, governance, AGM playbook - **Layer 2 — Segment HQ:** Strategic direction, segment-level M&A integration - **Layer 3 — Operating units (~135):** Sales, manufacturing, R&D execution - **Layer 4 — Acquisition pipeline:** External funnel + internal champions per vertical #### 4. Revenue Model Details **Revenue Type Breakdown (estimate)** [S2][S4] - Original equipment / instrumentation sale: ~65% - Aftermarket / service / parts: ~25% - Software & data services: ~10% (growing post-FARO) **Pricing Power** - Mission-critical instruments (process safety, aerospace) command premium pricing - Recent commentary: pricing +2-4% annually across cycles - Operational excellence absorbs cost inflation, preserves margin **Sales Cycles** - EIG Process & Analytical: 6-12 months (capital sale) - EIG Aerospace & Power: 12-24 months (qualification cycles) - EMG Automation: 3-9 months - EMG Aerospace specialty metals: 9-18 months (LTAs) #### 5. Comparison to Peers (business model) - **vs. Roper (ROP):** ROP has pivoted to vertical software (~60% of revenue); AMETEK remains hardware-instruments. AMETEK has lower switching costs per unit but higher diversification. - **vs. Mettler-Toledo (MTD):** MTD is more concentrated (4 product platforms); AMETEK is more diversified (~135 units). MTD has higher margin per platform but less optionality. - **vs. Fortive (FTV):** Both compounder-style; FTV invested more heavily in healthcare; AMETEK kept industrial focus. AMETEK's margin profile has held up better since 2022. #### 6. Risks & Watchpoints (model layer) - **M&A dependence** — without ~$500M-$1B/yr in deal activity, growth model degrades to organic-only 3-4%. - **Decentralization tradeoff** — 135 business units = harder to drive cross-portfolio innovation/platform leverage. - **Cyclical end-markets** — when 3-4 verticals draw down simultaneously (e.g., 2020, brief 2023), the diversification benefit is real but not bulletproof. - **Acquisition multiple inflation** — pre-synergy multiples have crept from 6-8x EBITDA (2010s) to 8-10x recent (Paragon, FARO). #### 7. Variant Perception Setup - **Consensus view:** AMETEK = boring quality compounder, deserved 28-32x P/E. - **Bull variant:** Q1 2026 order acceleration ($2.2B record, +22% organic) suggests cyclical upside on top of secular compound. Could re-rate to 32-35x on beat-and-raise pattern. - **Bear variant:** 34x P/E already reflects perfection; any slip in organic growth or margin = multi-quarter de-rating. #### 8. Source Index [S1] AMETEK 10-K FY2025 (filed 2026-02-17), Business section. [S2] AMETEK 10-K FY2025 + 10-Q Q1 2026 segment disclosures. [S3] AMETEK Investor Presentation (Q1 2026, FY2025 review). [S4] Tavily web search — AMETEK Growth Model, segment mix, retrieved 2026-05-28. --- NEXT: Step 02 — Industry & Market ## Financial Snapshot --- source: coverage-next-full type: step step: 04 title: Financial Snapshot & Quality ticker: AME generated: 2026-05-28 --- ### Step 04 — Financial Snapshot & Quality: AMETEK #### 1. Executive Summary AMETEK's reported P&L is **high quality** — minimal one-time items in recent years (2021-2025), no aggressive revenue recognition policies, low DSO, modest goodwill impairment risk despite ~45% of assets in goodwill. Adjustments are mostly de minimis (acquisition-related amortization, restructuring, integration costs — typical for an acquirer). FCF conversion (FCF/NI) consistently >100%, with 2025 at ~113%, reflecting capital-light business model relative to revenue. The most material judgment items are (1) ~$7.2B in goodwill against $10.6B of equity — large but supported by 12.8% ROIC and continuing portfolio cash generation; (2) pension obligations with funded status that swings 200-300bps year to year; (3) ~$1B in net intangibles being amortized over 10-20 years. **Adversarial sweep: clean** — no active investigations, no material lawsuits beyond routine, no short-seller reports of substance. #### 2. Key Data Points **Income Statement Quality (FY2021–FY2025)** [S1][S2] | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---:|---:|---:|---:|---:| | Revenue | 5,547 | 6,151 | 6,597 | 6,941 | 7,401 | | GAAP Op Income | 1,309 | 1,501 | 1,707 | 1,780 | 1,910 | | Adj Op Income | ~1,460 | ~1,640 | ~1,840 | ~1,920 | ~2,005 | | GAAP Net Income | 990 | 1,160 | 1,313 | 1,376 | 1,480 | | Adj Net Income | ~1,100 | ~1,260 | ~1,420 | ~1,495 | ~1,720 | | GAAP EPS Dil | 4.25 | 5.01 | 5.67 | 5.93 | 6.40 | | Adj EPS | 4.71 | 5.45 | 6.13 | 6.43 | 7.43 | | OCF | 1,160 | 1,149 | 1,735 | 1,829 | 1,802 | | FCF | 1,050 | 1,010 | 1,599 | 1,702 | 1,672 | **Quality Ratios** [S1][S2] - FCF / Net Income (FY25): 113% — very strong conversion - OCF / Revenue (FY25): 24.3% — top-tier industrial - Receivables DSO (FY25): ~52 days — stable - Inventory days (FY25): ~85 days — slight inflation post-Paragon - Capex / D&A (FY25): ~0.5x — capital-light vs. heavy industrial peers (1.0-1.5x typical) - Cash conversion cycle: ~95 days — typical instruments **GAAP-to-Adjusted Bridge (FY2025)** [S2] - GAAP EPS: $6.40 - + Acquisition-related amortization: ~$0.80 - + Acquisition transaction costs: ~$0.15 - + Pension non-service costs: ~$0.05 - + Restructuring: ~$0.03 - = Adj EPS: ~$7.43 #### 3. Adversarial Research Sweep **Short reports / activist filings:** None identified. No 13D filings of activist character. No prominent short-seller reports (Muddy Waters, Hindenburg, etc.) targeting AMETEK in recent years. Short interest stable at low single digits %. **SEC investigations / enforcement:** No active material SEC matters disclosed in FY2024 or FY2025 10-K filings. Routine periodic filing without restatements. **Lawsuits / litigation:** Routine litigation in normal course (product liability, IP). Most-recent 10-K filings disclose no contingent loss accruals materially impacting financial statements. **Accounting concerns:** None flagged. - Goodwill impairment testing performed annually; no impairment in 2024 or 2025. - Revenue recognition under ASC 606 standard — no aggressive recognition patterns flagged. - Effective tax rate stable (~20%) across years; no major tax controversy. **Whistleblower / FCPA:** No active matters disclosed. **Aggressive M&A accounting:** Bolt-on acquisitions are accounted for at fair value with allocations to identifiable intangibles, goodwill. Amortization patterns appropriate. ROIC tracking validates that purchased revenue is materializing (ROIC ~13%; cost of capital ~8%). **Pension obligations** [S1] - DB pension funded status: ~85% (FY2025 estimate) - Underfunded by ~$200-300M; offset by overfunded UK plan - Manageable; not a stress point **Verdict: CLEAN.** No material adversarial flags. Quality of earnings holds up to scrutiny. The most fair criticism is the size of goodwill ($7.2B) relative to equity ($10.6B) — but ROIC ramp and consistent cash generation defend the carrying value. #### 4. Sustainable Earnings View **Adjusted EPS trajectory (5-year)** [S2] | FY | Adj EPS | YoY% | |---|---:|---:| | 2021 | $4.71 | +14% | | 2022 | $5.45 | +16% | | 2023 | $6.13 | +12% | | 2024 | $6.43 | +5% | | 2025 | $7.43 | +16% | | **5yr CAGR** | | **+12.0%** | **Quality of growth assessment:** - Organic + M&A combined revenue +6-8%/yr → translates to ~12% EPS via margin expansion + buyback + tax efficiency - This is the AMETEK Growth Model algorithm working as designed - No accounting "stretch" required to hit these numbers #### 5. Financial Sufficiency for Forecast **PASS for forecast.** Sustainable earnings power is well-supported by: - 9 years of clean GAAP-to-adjusted bridge - FCF conversion >100% over 5-year period - Margin trajectory consistent across business cycles (no margin collapse in 2020) - Tax rate stable #### 6. Risks & Watchpoints (quality layer) - **Goodwill carrying value at $7.2B** — would need broad portfolio impairment to materially hit equity - **Capitalized M&A intangibles** — being amortized; $2-3B remaining; ~$240M/yr drag on GAAP - **Pension underfunding** — manageable but watchable in rising-rate or down-cycle scenarios - **Acquisition accounting opacity** — common across compounder peers; reasonable disclosure quality at AMETEK #### 7. Adjustments to Reported P&L (recommended for valuation) - Add back acquisition amortization to operating income (since these are real, not capital-destroying expenses — ROIC validates this) - Treat restructuring as recurring (~$25-50M/yr typical) - Pension non-service costs: pass-through (volatile) #### 8. Source Index [S1] AMETEK 10-K FY2025 (filed 2026-02-17), MD&A and footnotes. [S2] AMETEK Q4 2025 + Q1 2026 8-K earnings releases (GAAP-to-adjusted reconciliations). [S3] Tavily web search — no adversarial flags identified, retrieved 2026-05-28. --- ADVERSARIAL_SWEEP: CLEAN FCF_CONVERSION: >100% NEXT: Step 05 — Quarterly Momentum ## Recent Catalysts --- source: coverage-next-full type: step step: 12 title: Catalysts / Bull-Bear (Analyst Debate) ticker: AME generated: 2026-05-28 --- ### Step 12 — Catalysts & Bull/Bear Debate: AMETEK > **Note:** Earnings call transcripts not loaded (coverage-next-full path). Analyst-debate structure inferred from consensus notes (Tavily), press releases, prepared remarks, and 8-K filings. No live Q&A read. #### 1. Executive Summary The current analyst debate on AMETEK centers on three vectors: **(1) order momentum durability** (Q1 2026 +22% organic orders — sustainable or pull-forward?), **(2) M&A pipeline / capital deployment quality** (FARO accretion timing, next big deal), and **(3) valuation** (34x trailing P/E — premium that demands continued execution). The Street is **constructive but split** — average price target $230 with median at $255 implies upside ~13-15% to optimist scenario. Bulls anchor on Q1 momentum + FARO + AGM compounding; bears on cycle vulnerability + multiple compression risk. Backlog of $3.87B and FY26 guidance raise ($7.94-$8.14 EPS) provide a more constructive setup than typical mid-cycle reads, but valuation is the binding constraint. #### 2. The Bull Thesis (3 bullets) **1. Order/Backlog Acceleration Provides 6-Month Forward Cover with +22% Organic Growth Signal** Q1 2026 orders hit $2.2B record (+23%, +22% organic). Backlog reached $3.87B (record), giving ~6 months of revenue coverage. EMG segment specifically saw +16% organic order growth — the strongest in 5+ quarters and a leading indicator for automation + aerospace + medical end markets through 2H 2026 and into 2027. This sets up the typical AMETEK "beat-and-raise" pattern for the remainder of FY26 [S1][S2]. **2. M&A Engine + AGM Playbook Continues to Compound at 15%+ Marginal ROIC** $10B+ deployed over the past decade at avg ~13-15% year-3 ROIC. FARO ($920M, July 2025) and Paragon ($1.9B, 2023) are the marquee recent deals, both on track for accretion. Balance sheet flex (net debt/EBITDA 0.8x) provides ~$3-4B of additional M&A capacity without strain. The AMETEK Growth Model algorithm (~3% organic + ~3-5pts M&A + margin expansion + tax efficiency + buyback) reliably delivers ~10-12% EPS growth across cycles — and current portfolio quality is the best in 10+ years. **3. Margin Expansion Continues with Operational Leverage at Record Levels** Q1 2026 core operating margin hit 27.9% (+160bps YoY), GAAP margin 26.8% (+90bps). Long-term trajectory: 21.0% (FY17) → 25.8% (FY25) = 480bps over 8 years. Future runway exists via FARO integration, Paragon scale-out, and pricing pass-through on aerospace LTAs. Adjusted operating margin could reach ~28% by FY27, supporting EPS growth of 12-15% even in moderate-organic-growth environment. #### 3. The Bear Thesis (3 bullets) **1. 34x Trailing P/E Demands Continued Perfection — Mean Reversion Risk to 27-30x** At ~$226 share price / FY25 GAAP EPS $6.40, P/E is ~34x; on adjusted EPS $7.43, P/E is ~30x. Both metrics sit at the top end of the 10-year range. Compounder peers (Fortive 22x, IEX 22x, Teledyne 18x) trade meaningfully lower; only Roper (30x) and Mettler-Toledo (25x) sit in similar zone. If organic growth slows from ~3% to ~1-2% or any operational hiccup, multiple compression toward 27-28x = ~$180-200 share price (-10 to -20%). The premium isn't large enough to justify shrugging off cyclical risk. **2. Order Surge May Reflect Tariff-Driven Pull-Forward — Sustainability Unclear** Q1 2026 +22% organic orders is genuinely strong, but the question is composition. With Section 301 tariffs already in place + threat of expansion (new policy environment in 2026), customers may have pulled forward purchases to lock in pre-tariff pricing. EMG specifically (which saw +16% organic orders) is heavily exposed to aerospace + automation customers that would rationally hedge tariff timing. If 30-50% of the order surge is pull-forward, then 2H 2026 - 1H 2027 could see book-to-bill drop back below 1.0x, validating the bear's de-rate concern. **3. M&A Pipeline Quality Risk + Multiple Inflation Erodes the Compounding Engine** The AMETEK acquisition multiple has crept from ~6-8x EBITDA pre-synergies (2010s) to ~8-10x recent deals (Paragon, FARO). If this trend continues — and the global private market remains competitive with PE firms — the marginal ROIC math degrades. Already, FY25 ROIC of 12.8% is below where one would expect after $5.7B of cumulative M&A from 2021-2025; the spread vs. WACC has not widened despite scale advantages. If the next 3-year M&A vintage delivers marginal ROIC of 10-12% (vs. historical 14-16%), the compounder thesis weakens materially. #### 4. Catalysts (next 4 quarters) **Near-term (next 3-6 months)** - Q2 2026 earnings (late July 2026): Test of Q1 2026 momentum sustainability + tariff impact commentary - FY26 EPS guidance reset: management likely to raise again if Q2 sustains; consensus $8.00 vs. midpoint $8.04 - FARO integration progress milestones - New bolt-on acquisition announcement (running 3-6/yr cadence; one likely each quarter) **Medium-term (6-12 months)** - 2027 outlook initial framing at Q4 2026 earnings - Defense budget appropriations cycle (Sept-Oct 2026) - China geopolitical / tariff dynamics - Potential larger acquisition deployment (~$1B+ scale, FARO follow-on) **Long-term (12-24 months)** - Margin trajectory toward 28% target - Marginal ROIC stabilization at 14-16% - Succession planning for CEO Zapico (currently 65) - Possible portfolio reorganization or divestiture (rare for AMETEK but historically EMG portions have been pruned) #### 5. Variant Perception The market is **slightly optimistic** on near-term order momentum and **appropriately skeptical** on M&A pipeline. The variant perception that could shift the stock: - **Upside variant:** order strength is durable + AGM continues to find margin uplift + FARO accretion exceeds plan → multiple expansion to 32-36x = $260-290 target - **Downside variant:** order surge fades into 2H 2026 + tariff hit absorbs margin gains → de-rating to 27-28x = $185-200 target Both paths are real; risk/reward is balanced near current levels. #### 6. Consensus vs. Variant Setup - Street median PT: $255 (top of $226 average target band) — implies the "upside variant" is the *modal* analyst case - Buyside positioning: institutions own 91% — large positions; not contrarian - Short interest: low single digits — no bear conviction - This is a "show-me" stock at premium valuation; needs Q2 and Q3 2026 to confirm the trajectory #### 7. Sources for /complete-coverage Step 15 (Scenarios) The Bull (§2), Bear (§3), and catalyst structure (§4) here directly feed /complete-coverage Step 15 scenario analysis. Suggested probability weights: - Bull case: 25% - Base case: 55% - Bear case: 20% #### 8. Source Index [S1] AMETEK Q1 2026 8-K earnings release (filed 2026-04-30). [S2] AMETEK Q1 2026 investor presentation. [S3] Tavily web search — analyst consensus / commentary, retrieved 2026-05-28. [S4] Cross-reference Steps 03 (revenue), 04 (quality), 09 (returns). --- #### Bull Case — Summary - Order/backlog acceleration provides 6-month forward cover with +22% organic growth signal - M&A engine + AGM playbook continues to compound at 15%+ marginal ROIC - Margin expansion continues with operational leverage at record levels #### Bear Case — Summary - 34x trailing P/E demands continued perfection — mean reversion risk to 27-30x - Order surge may reflect tariff-driven pull-forward — sustainability unclear - M&A pipeline quality risk + multiple inflation erodes the compounding engine --- NEXT: Step 16 — Variant Perception & Catalysts (deeper) / Step 17 / Step 18 / [/complete-coverage handoff for 13-14-15-19] ## Full Research Available This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear, management quality, earnings transcript analysis) is available via: - Investment memo: /memo/ame - Full research API: GET /api/v1/research/AME/memo - Coverage universe: /stocks